No abstract

BACKGROUND The objective of this study is to determine whether in a dialysis patient with prostate cancer leuprorelin acetate blood levels were abnormally high or low due to kidney failure or because of dialysis. METHODS Sustained‐release leuprorelin acetate 3.75 mg was given every 4 weeks for prostate cancer in a 79‐year‐old dialysis patient. Changes in serum level of leuprorelin acetate in this patient were measured before and after dialysis. RESULTS Leuprorelin acetate appeared to have a dialysance close to that of vitamin B12, which has a similar molecular weight. The amount dialyzed did not exceed 8.3% of the amount released per day. Mean blood levels of leuprorelin acetate, as measured in this patient, were higher (0.64 to 1.31 ng/ml) than those in prostate cancer patients with normal kidney function (mean ± SD, 0.24 ± 0.12 to 0.50 ± 0.32 ng/ml). CONCLUSIONS Sustained‐release leuprorelin acetate can be used safely in dialysis patients with prostate cancer. Prostate 34:191–194, 1998. © 1998 Wiley‐Liss, Inc.

We recommend this prosthesis as the first choice among testosterone-replacement therapies for hypogonadal men.

The patient was a 47-year-old male, who visited Hidaka Hospital with a chief complaint of swelling in the right inguinal region and the scrotum. With a diagnosis of a right spermatic cord tumor, right high orchiectomy was performed. Since an inflammatory type of malignant fibrous histiocytoma (MFH) was diagnosed from histopathological findings, chemotherapy and radiation therapy were performed as postoperative treatment. Malignant fibrous histiocytoma with the primary focus of the spermatic cords is a rare disease. To our knowledge, this is the 20th case of MFH of the spermatic cord in Japan (the 42nd in the world) and it is the second case of inflammatory type of MFH in Japan.

No abstract